Sionna Therapeutics will participate in investor events to discuss its novel cystic fibrosis treatments and pipeline advancements.
Quiver AI Summary
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for cystic fibrosis (CF), has announced its participation in upcoming investor events: the 8th Annual Evercore Healthcare Conference on December 3, 2025, and the Citi 2025 Global Healthcare Conference on December 4, 2025. The company aims to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, particularly by targeting stabilizing methods for its nucleotide binding domain 1 (NBD1), to enhance clinical outcomes and quality of life for CF patients. Sionna is advancing a pipeline of small molecules to correct genetic defects such as F508del and is also developing complementary CFTR modulators. Live webcasts and replays of the presentations will be available on their investor relations website.
Potential Positives
- Sionna Therapeutics is actively engaging with investors by participating in two significant healthcare conferences, which can enhance visibility and investor interest.
- The company is advancing a unique pipeline of medicines aimed at treating cystic fibrosis by specifically targeting the CFTR protein, which could lead to improved patient outcomes and attract attention in the biopharmaceutical sector.
- Sionna's focus on developing therapies for patients with the F508del mutation indicates a targeted approach to addressing a prevalent genetic defect, potentially positioning the company as a leader in cystic fibrosis treatment innovation.
- Live webcasts and replays of the investor presentations demonstrate Sionna's commitment to transparency and keeping investors informed, which can foster trust and confidence in the company.
Potential Negatives
- Participation in investor events may indicate the company is seeking additional funding or support, which could imply financial instability or a need for investor confidence.
- The focus on the CFTR protein and genetic mutation suggests that their approach is highly specialized, which may limit their market potential and lead to uncertainties in product development.
- The emphasis on compliance with Regulation FD suggests that the company might have faced challenges in providing timely updates, which could raise red flags for potential investors regarding transparency.
FAQ
What is Sionna Therapeutics known for?
Sionna Therapeutics develops novel medicines that aim to normalize the function of the CFTR protein for cystic fibrosis treatment.
When are the upcoming investor events for Sionna Therapeutics?
Sionna will participate in the Evercore Healthcare Conference on December 3rd and the Citi Global Healthcare Conference on December 4th, 2025.
How can I watch the presentations by Sionna Therapeutics?
Live webcasts of the presentations will be available on the "Events" page under the Investors section of Sionna’s website.
What is the focus of Sionna's research?
Sionna focuses on developing small molecules to correct defects caused by the F508del mutation and stabilizing the CFTR protein's NBD1 domain.
Where can I find more information about Sionna Therapeutics?
Additional information can be found on Sionna Therapeutics' website at www.sionnatx.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SION Insider Trading Activity
$SION insiders have traded $SION stock on the open market 103 times in the past 6 months. Of those trades, 1 have been purchases and 102 have been sales.
Here’s a breakdown of recent trading of $SION stock by insiders over the last 6 months:
- BRUCE BOOTH has made 0 purchases and 50 sales selling 698,418 shares for an estimated $22,085,831.
- CAPITAL MANAGEMENT, L.P. RA has made 0 purchases and 32 sales selling 509,961 shares for an estimated $20,262,761.
- MICHAEL CLOONAN (President & CEO) has made 0 purchases and 12 sales selling 200,000 shares for an estimated $6,327,621.
- ELENA RIDLOFF (CFO & Head of Corp. Dev.) has made 0 purchases and 7 sales selling 85,000 shares for an estimated $1,966,634.
- GP A, LLC TPG purchased 60,000 shares for an estimated $950,400
- JENNIFER FITZPATRICK (Chief Legal Officer) sold 10,250 shares for an estimated $236,980
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SION Hedge Fund Activity
We have seen 36 institutional investors add shares of $SION stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRAIDWELL LP removed 767,842 shares (-71.0%) from their portfolio in Q3 2025, for an estimated $22,582,233
- VANGUARD GROUP INC added 512,803 shares (+81.4%) to their portfolio in Q3 2025, for an estimated $15,081,536
- FRANKLIN RESOURCES INC removed 257,876 shares (-51.6%) from their portfolio in Q3 2025, for an estimated $7,584,133
- JENNISON ASSOCIATES LLC added 244,575 shares (+32.5%) to their portfolio in Q3 2025, for an estimated $7,192,950
- JPMORGAN CHASE & CO removed 242,562 shares (-10.9%) from their portfolio in Q3 2025, for an estimated $7,133,748
- ZIMMER PARTNERS, LP removed 237,500 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,120,625
- PRICE T ROWE ASSOCIATES INC /MD/ removed 223,478 shares (-25.9%) from their portfolio in Q3 2025, for an estimated $6,572,487
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SION Analyst Ratings
Wall Street analysts have issued reports on $SION in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/19/2025
- Freedom Capital Markets issued a "Buy" rating on 10/17/2025
- Jones Trading issued a "Buy" rating on 09/08/2025
- Raymond James issued a "Strong Buy" rating on 09/03/2025
To track analyst ratings and price targets for $SION, check out Quiver Quantitative's $SION forecast page.
$SION Price Targets
Multiple analysts have issued price targets for $SION recently. We have seen 5 analysts offer price targets for $SION in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Kambiz Yazdi from BTIG set a target price of $50.0 on 11/19/2025
- Ilya Zubkov from Freedom Capital Markets set a target price of $38.0 on 10/17/2025
- Debanjana Chatterjee from Jones Trading set a target price of $46.0 on 09/08/2025
- Brian Abrahams from RBC Capital set a target price of $22.0 on 09/03/2025
- Chris Raymond from Raymond James set a target price of $45.0 on 09/03/2025
Full Release
WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events:
- 8 th Annual Evercore Healthcare Conference on Wednesday, December 3 rd , 2025, at 12:30 p.m. ET; and
- Citi 2025 Global Healthcare Conference on Thursday, December 4 th , 2025, at 9:45 a.m. ET
Live webcasts of the presentations will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/ . Replays will also be available following the events.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit
www.sionnatx.com
.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
[email protected]
Investor Contact
Juliet Labadorf
[email protected]
